Helicobacter pylori colonizes the gastric mucosa and causes serious gastroduodenal disease [1] . The grade of gastritis is in part dependent on factors involved in bacterial attachment including the H. pylori blood group antigen-binding adhesin BabA [2] . Expression of BabA correlates with overt disease, such as peptic ulceration and adenocarcinoma [3, 4] . In a transgenic
Helicobacter pylori colonizes the gastric mucosa and causes serious gastroduodenal disease [1] . The grade of gastritis is in part dependent on factors involved in bacterial attachment including the H. pylori blood group antigen-binding adhesin BabA [2] . Expression of BabA correlates with overt disease, such as peptic ulceration and adenocarcinoma [3, 4] . In a transgenic mouse, expression of the human Lewis b antigen (Le b ) facilitated adherence of H. pylori to the gastric epithelium and increased host inflammatory responses, compared with that of the wild-type mouse [5] . An additional H. pylori adhesin, the sialic acid-binding adhesin (SabA), was identified with specificity for sialyl-Lewis x antigen (sLe x ) [6] . Expression of sLe x in gastric mucosa is much increased after induction of chronic inflammation. SabA binds to sLe x and other similar a2.3-sialylated glycoconjugates and provides an additional adherence mechanism during life-long and persistent H. pylori infection.
Treatment of infection involves a combination of antibiotics and a proton-pump inhibitor (triple or quadruple therapy), but the prevalence of antibiotic resistance is increasing [7, 8] . Development of compounds that inhibit interaction of H. pylori with host receptors may provide an alternative approach to prevent infection. Neoglycoproteins of the Le b or sLe x oligosaccharides conjugated to human serum albumin (HSA) inhibited BabA-or SabA-mediated adhesion, respectively, of H. pylori to gastric mucosa in vitro [6] ; however, the costs of production may preclude their development as anti-infective agents. Naturally occurring glycoconjugates in human and porcine milk also prevent H. pylori adhesion in vitro [9, 10] , and studies using porcine milk showed inhibition in vitro and in a murine model of infection [11] .
In the present study, we investigated novel inhibitors of H. pylori adhesion, domain antibodies directed against BabA, and 2 glycoconjugates of Le b multivalently coupled to poly-d-lysine. Domain antibodies correspond to the variable regions of either the heavy (V H ) or light (V k ) chains of human antibodies [12] [13] [14] . We describe testing of V k domain antibodies with specificity for BabA in a variety of systems for inhibition of H. pylori adhesion. In contrast to conventional antibodies, domain antibodies are well expressed in bacterial, yeast, and mammalian cell systems and may be well suited for use as compounds to prevent H. pylori attachment to gastric epithelium. 
MATERIALS AND METHODS

Purified
H. pylori Isolates
H. pylori wild-type strain J99, single babA and sabA mutant strains, and the double babAsabA mutant strain were kindly provided by Thomas Borèn [6] . H. pylori strains J99 (and mutants), NCTC 11637, and CCUG17875 were grown for 2-3 days on Columbia agar plates supplemented with 5% horse blood (Oxoid) at 37ЊC under micro-aerobic conditions. Bacterial cell numbers in suspension were determined by optical absorbance at 600 nm (Ultrospec II; LKB) and were correlated with total viable counts. 1 ϫ 10 isothiocyanate isomer I (Sigma) and were resuspended in phosphate-buffered saline (PBS). Labeling was confirmed by flow cytometry (FACSCalibur; Becton Dickinson).
Le b Glycoconjugates
Lactose b1-O-(3-benzyloxycarbonylamino propane) was selectively protected in the 3'-position with p-methoxybenzyl chloride-dibutyltin oxide. The remaining hydroxyls were benzylated with benzyl bromide-sodium hydroxide under phase transfer conditions. The p-methoxybenzyl group was removed using ceric ammonium nitrate under standard conditions. The resulting disaccharide acceptor was glycosylated with 1-thioethyl 3,4,6 tri-O-acetyl N-trichlorooxycarbonyl glucosamine with use of N-iodosuccinimide-trifluoromethanesulfonic acid activation.
The trichlorooxycarbonyl group was replaced with an acetyl group by using zinc dust and then acetic anhydride. The Oacetyl groups were removed with sodium methoxide. The modified trisaccharide was then converted to Le b hexasaccharide derivative [15] . The resulting Le b hexasaccharide with a free amine group at the reducing end of a 3 carbon chain was conjugated to poly-d-lysine: 3 mg was reacted with a large molar excess (35 mg) of pimelic acid dipentafluorophenyl ester, and the resulting extended chain ester activated hexasaccharide was purified by reverse-phase chromatography, rapidly isolated by low-temperature high-vacuum evaporation, dissolved in dimethylsulfoxide, and reacted with a solution of poly-d-lysine (2 mg) in dimethylsulfoxide (at room temperature for 2 days). The final product was diluted with water and was freeze-dried, yielding high-purity multivalent ) was synthesized as described elsewhere [16] .
Production and Screening of Domain Antibody Library
The domain antibody phage libraries were based on a single human antibody framework for V H (DP47/JH4b) and for V k (DPk9/Jk1). Amino acid side chain diversity was introduced through DNA nucleotide diversification at positions naturally diversified in the mature human repertoire. Selections against passively coated BabA from H. pylori strain CCUG17875 were performed essentially as described elsewhere [17] , with the exception that bound phage were eluted at room temperature for 10 min with 500 mL of PBS containing 1 mg/mL trypsin (Sigma-Aldrich) supplemented with 0.1 mmol/L calcium chloride (Sigma-Aldrich). After selection rounds 2 and 3, the enriched domain antibody genes were subcloned into the soluble domain antibody expression vector pDOM5 and used to transform Escherichia coli HB2151 for further analysis.
Supernatents (100 mL) from individual E. coli HB2151 clones transformed with domain antibody DNA were analyzed for BabA binding activity with use of enzyme-linked immunosorbent assay using 9E10 antibody (anti-myc; Sigma-Aldrich) to detect bound domain antibody. Forty-three unique binding clones (by DNA sequence) were grown at 37ЊC with shaking at 250 rpm in 2ϫ TY (50 mL) supplemented with 50 mg/mL carbenicillin and 0.1% glucose. Isopropyl-b-d-thiogalactopyranoside (1 mmol/L) was added when the optical density at 600 nm reached 0.8, and cultures were incubated overnight at 30ЊC with shaking. Cells were pelleted by centrifugation (3450 g for 10 min), and supernatants (50 mL) were mixed by rotation at 50 rpm with 200 mL of protein-l-sepharose (Sigma-Aldrich) for V k domain antibodies or protein-A streamline (GE Healthcare) for V H domain antibodies at room temperature for 1 h. The resins were recovered by centrifugation (220 g for 1 min), transferred to a 96-well paper-filter plate (Whatman), and then washed twice with 0.5 mol/L sodium chloride in PBS (2 ϫ 1 mL) and PBS ( mL). Domain antibodies were eluted with 2 ϫ 1 0.1 mol/L glycine (pH, 2.0; 210 mL) and were neutralized with 1 mol/L Tris-hydrochloric acid (pH, 8.0; 40 mL).
Bacterial Binding Assays
Binding of whole cells and BabA to Le b -HSA was determined by surface plasmon resonance (SPR) using the Biacore X (whole cells and BabA proterin) or Biacore J (whole cells only; GE Healthcare). 
Histological Sections of Human Stomach
Formalin-fixed Le b -expressing H. pylori-negative biopsy samples of human stomach were cut into 5-mm sections with use of a Leica SM2400 rocking microtome and were collected on Vectabond-coated slides (Vector Laboratories). Antigen expression was optimized by boiling (15 , respectively). The antibodies were generously donated by Dr. J. Bara (Hô pital St-Antoine; Paris, France).
Binding and binding-inhibition assay. Tissue sections were incubated for 30 min in a humid atmosphere with 200 mL of blocking buffer PBS, 2% bovine serum albumin, and 0.05% Tween-20 (PBST) per slide before washing (3 times). Suspensions of fluorescein isothiocyanate isomer I H. pylori ( cfu/mL) and inhibitor with protein L (1 mg/mL; for 8 1 ϫ 10 domain antibodies only) were incubated with gentle shaking for 2 h and washed with blocking buffer. Propidium iodide (200 mL of 5 mg/mL) was added to each slide for 3 min. Slides were washed twice in PBST, air-dried, and mounted with Vectashield (V-1000; Vector Laboratories). All incubation and washing steps were performed in the dark at room temperature.
Combinations of inhibitors were also assessed. Removal of bound H. pylori. To measure removal of H. pylori, inhibitors were incubated with tissue samples to which H. pylori was attached. Sections were then washed 3 times in PBST, stained with propidium iodide, washed in PBST, and mounted as previously described.
Quantification of Binding
Sections were observed using a Laser Scanning Confocal Microscope (Zeiss: Axiovert 100 TV) with a ϫ20 Zeiss LD-ACHR objective. Digital images of sections were analyzed and quantified using Metamorph software [18] Figure 1B ). For improved kinetic analyses, BabA was injected at a higher flow rate (60 mL/min) over the sensorchip surface with relatively low levels of immobilized Le b -HSA. Representative sensorgrams indicated an improved fit to the linkedreaction model ( Figure 1D ). To investigate this further, the contact time of BabA was varied (10 s, 30 s, and 60 s), and under these conditions, the apparent dissociation rate decreased with increasing contact time ( Figure 1E and 1F) , which is consistent with the linked-reaction fitting model. In the absence of evidence for bivalent binding of BabA, a 2-step conformational-change model was used to describe formation of the BabA -Le b -HSA complex. The apparent
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2 ϫ 10 L (calculated from sensorgrams generated under conditions used for those shown in Figure 1D) Inhibitory activity of domain antibodies in stomach tissue model. Domain antibodies 25 and 28 (with protein L) were assessed for their ability to inhibit adhesion of H. pylori 11637 to histological sections of Le b human stomach and were compared with the negative control domain antibody HEL4. Domain antibody 28 inhibition was no greater than that of domain antibody HEL4. In contrast, domain antibody 25 inhibited dose-dependently, with 73% inhibition at 100 mg/mL (∼8 mmol/ L) ( Figures 3A and 4A and 4B ). This was significantly higher than that achieved with the control ( ) and, compared P ! .01 with binding in the absence of domain antibodies, was very highly significant ( Figure 3B ). Le b -HSA P ! .01 also inhibited in a dose-dependent manner but was less effective, with 60% inhibition at 250 mg/mL ( ), and sLe x P p .01 inhibition reached a plateau of ∼40% at 100 mg/mL ( ) P 1 .05 ( Figure 3B -HSA increased inhibition to 96% at 10 mg/mL of each inhibitor and 93% at 50mg/mL of each inhibitor ( ), respectively ( Figure 3C and 3D ). Combi-P ! .001 nation of sLe x with domain antibody 25 increased the inhibition of binding from 20% to 40% at 10mg/mL (each inhibitor) and from 35% to 60% at 50 mg/mL ( ). At the higher con-P ! .05 centration of 100 mg/mL, there was little increased effect on inhibition of binding, which was, in any case, almost maximal ( Figure 3E Candida albicans, Streptococcus pneumonia, and H. pylori (as detailed in this article) [19] [20] [21] [22] [23] .
In the present study, we describe a human V k domain antibody that inhibits attachment of H. pylori to human stomach epithelium. Forty-three independent V k domain antibodies that bound BabA, isolated from the phage library, were . Binding studies with chimaeric BabA constructs indicate that the BabA binding site is within residues 212-614 [24] . Domain antibodies have potential for topical application to prevent infection with H. pylori. In previous studies, domain antibodies that blocked adhesion mediated by the MP65 mannoprotein adhesin and that secreted aspartyl proteases of C. albicans cleared infection when applied vaginally in a rat model of vaginal candidiasis [20] . Furthermore, orally administered lactobacilli engineered to express single-domain (llama-derived) antibody fragments directed against surface components of rotavirus conferred protection against diarrhea in a mouse model of rotavirus infection [25] . These studies indicate that single-domain antibody fragments are sufficiently stable to retain activity at mucosal surfaces and that Fc-mediated function is not essential for protection against infection. In addition to stability, domain antibodies can be produced on a large scale by fermentation in microbial systems and can also be modified by in vitro affinity maturation to increase affinity using phage display technology [13, 14] . Affinity maturation could potentially increase the efficacy of domain antibody 25. Because gastric mucosal Le b and microbial BabA molecules are exposed on the membrane surfaces as multiple copies, it could be advantageous to present the domain antibodies themselves as multivalent structures (eg, by incorporation into micelles).
We also investigated glycoconjugates as inhibitors of H. pylori adhesion. In agreement with previous findings [6] , both Le b -HSA and, to a lesser extent, sLe x inhibited attachment of H. pylori to human stomach epithelium. Poly-d-lysine glycoconjugates represent a synthetic alternative to neoglycoprotein con-jugates, which not only provide a means of oligomerising Le b and, hence, increase the avidity of the inhibitor, but also make use of a protease-resistant backbone to which Le b can be coupled. The Le b hexasaccharide conjugated to poly-d-lysine was as potent an inhibitor as Le b -HSA in molecular assays but was more potent as an inhibitor of attachment of H. pylori to human stomach epithelium. In addition, the Le b hexasaccharide conjugated to poly-d-lysine was 100-fold more effective than Le b -HSA in removing adherent H. pylori from human stomach tissue sections. Protease resistance of the poly-d-lysine backbone may be a significant factor in this increased efficacy. This demonstration that the inhibitors can displace adherent H. pylori is of great importance, because it suggests that, in addition to prophylactic treatment, topical application of adhesion-blocking compounds may have therapeutic potential for infected individuals. In contrast to the Le b glycoconjugates, domain antibody 25 was ineffective at removing H. pylori when added after adherence of the bacteria, possibly reflecting the 2-log lower affinity for BabA, compared with Le b -HSA, which would again increase the desirability of multivalent presentation discussed above.
Use of combinations of inhibitors (sLe x with Le b conjugates or with domain antibody) may be a more effective strategy in preventing attachment of H. pylori. At low concentrations of each inhibitor (10 mg/mL), the inhibitory effects were synergistic, achieving almost complete inhibition, although at high concentrations (100 mg/mL), there was little increased effect on the inhibition.
An attractive future development might be to incorporate numbers of the active groups of these potentially synergistic partners on individual gold nanoparticles [26] or micelles. By presenting a high concentration of the inhibitors on the nanoparticles to the microbial surface, the effect may be to enhance inhibition of binding. Alternatively, the inhibitors may be linked to gold + iron nanoparticles and, once specifically bound to the organism, may be exposed to a variable magnetic flux, thereby rapidly heating the nanoparticles and killing the microorganism, irrespective of its antibiotic sensitivity.
